CostrymCostrym
Book a meeting
The asset class no one could access. Until now.

Invest in the best asset class in crypto.

Drug development programs are the most inaccessible asset class in the world. We tokenize them so anyone can invest. Verified programs, milestone USDC yields, and a minimum exit price — locked before you commit a single dollar.

Get started
The numbers
  • $1.5TGlobal drug development market
  • USDCMilestone payouts on-chain
  • LockedMinimum exit price set on day one
  • 12–24moCapital commitment to potential approval
  • One SPVOne program · full transparency
02The Numbers

Drug development has quietly generated some of the highest returns in the history of investing.

A single approved drug generates billions. Costrym opens that door for every investor on the blockchain — proprietary deal flow, validated programs, tokenized into a single SPV with verified terms, milestone USDC cashflows, and a minimum exit price set before capital moves.

$1.5T
Global drug development market
Highest
Returning asset class on record
Zero
Other platforms with structured access
On-chain
Liquid · traceable · verified

The IP is protected for decades. The market is global. Demand is inelastic. People will always need medicine.

The structure didn't exist. Until now.

03Why Drug Development Programs

Every major asset class has been tokenized. None come close to the return profile of drug development.

A single approved drug generates billions in recurring revenue.

The IP is protected for decades. The market is global. The demand is inelastic. People will always need medicine. The reason this asset class stayed out of reach is not because the returns weren't there — it's because the structure to access it didn't exist for anyone outside the institutional world.

Until now.

By the numbers
  • Real estate4–8% yield
  • Treasury-backed RWAs5–6% yield
  • Private creditMid-single digits
  • Drug developmentDifferent category

Institutions have known this for decades. The only thing that changed is access.

Different return profile. Different category.

04What Makes This Different

Most RWAs are illiquid, opaque, and lag reality. Costrym is built differently.

Other RWAsLocked & lagging

The standard problem.

  • Illiquid — locked behind fund structures with no exit path
  • Opaque — quarterly reporting that lags reality by 90 days
  • No validation — investors carry diligence risk themselves
  • Payouts only at the end — capital tied up for years with no checkpoints
CostrymOne program · one SPV

Liquid, traceable, validated.

  • Liquid — tokens tradeable on regulated secondary markets between accredited investors
  • Traceable — every transfer, milestone verification, and USDC payout is on-chain and permanent
  • Validated — every program clears full clinical and regulatory review before reaching investors
  • Paid at every checkpoint — USDC distributes automatically at each verified milestone

Your floor is set before capital is committed. No renegotiation. No discretion. No surprises at the finish line. The upside is open.

Minimum exit price locked on day one.

05The Costrym Edge

You invest after the work is done. Not before.

If a program doesn't meet the bar, it doesn't reach the platform. This is the institutional due diligence process — applied before capital is committed, not after.

It is the same information advantage that specialist pharma funds have charged 2-and-20 for. On Costrym, it is built into every deal.

  • 01
    Pre-clinical cleared

    Every program has passed the most risky phase before reaching the platform

  • 02
    Clinical data review

    Prior trial data is reviewed in full before any program is offered

  • 03
    Path to approval

    The program's regulatory path is mapped before a single offer is made

  • 04
    Detailed performance research

    Prior performance is reviewed for maximum due diligence

06How It Works

Four steps from access to payout. Verified programs, USDC at every checkpoint.

  1. 01ApplyVerify accreditation
  2. 02ReviewFull program breakdown
  3. 03InvestBuy program tokens
  4. 04Get paidUSDC at each milestone
Stage 01 / 04
01
Accredited investor verification
Step 01 — Apply·Apply

Submit your details and verify accreditation.

After accredited investor verification you receive access to the investor portal — active programs, full program summaries, milestone schedules, and SPV terms.

One program. Complete transparency.

Not a fund. Not a basket. One asset, one SPV, full visibility into every term and every milestone from the moment you invest until the moment you exit.

07Who This Is For · FAQ

On-chain capital, meet real-world yield.

You have on-chain capital looking for real yield from real assets. You understand SPV structures. You are an accredited investor who can hold a position for a 12–24 month window.

The institutional world has allocated to drug development programs for decades. You now have the same access — same information quality at entry — liquid, on-chain, and with terms locked before you invest.

  • Real estate yields 4–8%. Treasury-backed RWAs yield 5–6%. Drug development programs — with IP protection, global demand, and inelastic markets — operate in a completely different return category. Institutions have known this for decades. The only thing that changed is access.

  • Every program goes through a full clinical data review before it reaches investors. The signal is confirmed, the path to approval is mapped, and terms are structured before capital is raised. If the program doesn't pass validation, it doesn't reach the platform. This is the due diligence step that institutional pharma funds have historically kept proprietary.

  • A single-program SPV tied to one specific drug development program. Your tokens represent your economic interest in that SPV — milestone USDC payouts as the program progresses and a pre-agreed minimum exit price on approval.

  • Yes. Tokens are tradeable on regulated secondary markets between accredited investors. Every transfer is traceable on-chain. This is not a locked fund with no exit path. Liquidity is built into the structure from day one.

  • You keep every milestone payout already distributed. Capital beyond what was returned through milestones is at risk of total loss. This is disclosed in full before any commitment is made.

  • At each verified program milestone — enrollment completion, interim readout, safety review, final endpoint. Payouts are automatic. No discretion. No delays.

  • 12–24 months from capital commitment to potential approval depending on program. Milestone payouts begin distributing during the program — not at the end.

  • Yes. Tokens represent economic interests in an SPV and are structured as securities under US law. Offered exclusively to accredited investors under SEC Regulation D Rule 506(c). Costrym does not operate in jurisdictions where such offerings are prohibited.

  • Apply to gain investor portal access. Accredited investor verification is required before deal materials are shared. Deal flow is not public.

08Investor Terms

Validated. Verified. Locked.

Investor Terms
#COSTRYM / SPV
Structure
One SPV
one program · full visibility

Single-program SPV tied to one specific drug development program. Tokens represent your economic interest — milestone USDC payouts and a pre-agreed minimum exit price on approval.

What you get
  • Milestone USDC payoutsIncluded
  • Minimum exit price locked on day oneIncluded
  • Liquid tokens on regulated secondary marketsIncluded
  • Full on-chain traceabilityIncluded
EligibilityReg D 506(c)
09Get Started

The institutional world has had this access for decades. Now you do.

costrym ~ investor intake
$ apply --type=accredited
→ verification unlocks the investor portal — active programs, milestone schedules, SPV terms
$ contact --to=costrym@budera.app

Apply below. Accredited investor verification is required before deal materials are shared. Deal flow is not public.

Book a 15-min introcostrym@budera.app

For informational purposes only. Not an offer to sell or solicitation to buy any security. All investments carry risk including total loss of capital. Consult your legal and financial advisors before investing.